Legend Biotech Corp ADR [LEGN] stock is trading at $22.53, down -1.96%. An important factor to consider is whether the stock is rising or falling in short-term value. The LEGN shares have gain 5.87% over the last week, with a monthly amount drifted -20.08%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Legend Biotech Corp ADR [NASDAQ: LEGN] stock has seen the most recent analyst activity on October 07, 2025, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $40. Previously, Redburn Atlantic started tracking the stock with Buy rating on October 08, 2024, and set its price target to $86. On June 17, 2024, Truist initiated with a Buy rating and assigned a price target of $88 on the stock. H.C. Wainwright reiterated its Buy rating and decreased its price target to $73 on May 24, 2024. Deutsche Bank initiated its recommendation with a Buy and recommended $60 as its price target on May 23, 2024. Scotiabank upgraded its rating to Sector Outperform for this stock on April 17, 2024, but kept the price target unchanged to $65. In a note dated April 03, 2024, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $82 on this stock.
Legend Biotech Corp ADR [LEGN] stock has fluctuated between $21.19 and $45.30 over the past year. Currently, Wall Street analysts expect the stock to reach $61.2 within the next 12 months. Legend Biotech Corp ADR [NASDAQ: LEGN] shares were valued at $22.53 at the most recent close of the market. An investor can expect a potential return of 171.64% based on the average LEGN price forecast.
Analyzing the LEGN fundamentals
Legend Biotech Corp ADR [NASDAQ:LEGN] reported sales of 909.83M for the trailing twelve months, which represents a growth of 70.21%. Gross Profit Margin for this corporation currently stands at 0.62% with Operating Profit Margin at -0.27%, Pretax Profit Margin comes in at -0.38%, and Net Profit Margin reading is -0.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -0.31 and Total Capital is -0.15. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.37.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 22.28 points at the first support level, and at 22.03 for the second support level. However, for the 1st resistance point, the stock is sitting at 22.86, and for the 2nd resistance point, it is at 23.19.
Ratios To Look Out For
For context, Legend Biotech Corp ADR’s Current Ratio is 2.86. On the other hand, the Quick Ratio is 2.80, and the Cash Ratio is 1.0. Considering the valuation of this stock, the price to sales ratio is 4.57, the price to book ratio is 4.11.
Transactions by insiders
Recent insider trading involved GenScript Corporation, Affiliate, that happened on Nov 17 ’25 when 0.2 million shares were purchased. Director, Casey Patrick John completed a deal on Sep 26 ’25 to buy 1000.0 shares. Meanwhile, Officer Huang Ying bought 1370.0 shares on Sep 24 ’25.
